Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 17/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25846851 | 0.79 | LOXL2 (0.52) | MAPTKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL5459975 | 0.78 | MAPT (0.48) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL5017627 | 0.78 | MAPT (0.48) | MAPTKDM4EMEN1POLBKMT2A | |
| SCHEMBL14075492 | 0.77 | MAPT (0.41) | MAPTKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL7119359 | 0.75 | ALDH1A1 (0.48) | MAPTKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL2340487 | 0.75 | MAPT (0.48) | MAPTKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL8596016 | 0.75 | MAPT (0.48) | MAPTKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL30002633 | 0.75 | MAPT (0.48) | MAPTKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL3820241 | 0.75 | MAPT (0.48) | MAPTKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL18617684 | 0.75 | MAPT (0.48) | MAPTKDM4EMEN1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | MAPT 3856/4885KDM4E 2778/4885MEN1 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.